A composite probiotic composition having a significant improvement effect on hyperlipidemia

The intestinal flora is regulated through the complex probiotic composition, and the problem of high cholesterol and low-density lipoprotein levels in the blood in hyperlipidemia is solved, which significantly improves the symptoms of hyperlipidemia, and has high prevention and treatment in drugs. The application value of lipidemia.

CN114848684BActive Publication Date: 2024-12-03内蒙古科拓生物有限公司
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210301358.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-03-24
Publication Date
2024-12-03
Estimated Expiration
2042-03-24

AI Technical Summary

Technical Problem

The prior art is difficult to effectively prevent, alleviate or treat hyperlipidemia, especially the high cholesterol and low-density lipoprotein cholesterol levels in the blood.

Method used

A complex probiotic composition, including Lactobacillus casei Zhang, Bifidobacteria animal lactis subspecies V9, Lactobacillus planta P-8, Lactobacillus rhamnosus Probio-M9 and Bifidobacteria lactis Probio-M8, by regulation Intestinal flora, which significantly improves the symptoms of hyperlipidemia, is used to prepare drugs that lower cholesterol and low-density lipoprotein in the blood.

Benefits of technology

Complex probiotic composition significantly reduces the content of LDL-C and TC in the blood, increases the content of HDL-C, inhibits the increase of D-lactic acid and diamine oxidase, reduces visceral fat, improves the symptoms of hyperlipidemia, and has a greater degree of Application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114848684B_ABST
    Figure CN114848684B_ABST
Patent Text Reader

Abstract

The invention provides a composite probiotic composition with obvious improvement effect on hyperlipidemia, comprising: Lactobacillus casei Zhang; Bifidobacterium animalis subsp. lactis V9; Lactobacillus plantarum P‑8; Lactobacillus rhamnosus Probio‑M9 and Bifidobacterium lactis Probio‑M8. The composite probiotic composition has the effects of preventing, alleviating, assisting in the treatment or treating hyperlipidemia, and has great application prospects in the preparation of products for alleviating and treating such diseases as hyperlipidemia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of probiotics, and in particular to a composite probiotic composition having a significant improvement effect on hyperlipidemia. Background Art

[0002] Hyperlipidemia, also known as hyperlipoproteinemia, refers to the process of fat metabolism in which the levels of several lipids in the plasma are higher than normal, mainly manifested as higher serum cholesterol (TC), triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C) than normal levels. According to epidemiological and clinical medical studies, higher cholesterol levels in the blood than normal levels are positively correlated with the occurrence of cardiovascular disease (CVD). It has been reported that when the cholesterol level is 1mmol / L higher than the normal level (>5.2mmol / L), the risk of coronary heart disease increases by 35%. At the same time, reducing the cholesterol level in the serum by 1% can reduce the risk of cardiovascular and cerebrovascular diseases by 2% to 3%. The main cause of cardiovascular disease is atherosclerosis, and one of the risk factors for atherosclerosis is hypercholesterolemia.

[0003] Probiotics are usually defined as a class of active microorganisms that can regulate and improve intestinal flora and promote human health when the body ingests sufficient amounts from the diet. Probiotics are generally divided into three categories: lactic acid bacteria, bifidobacteria, and others. The criteria for designating a commensal strain as a probiotic include non-pathogenicity, human origin, acid and bile salt tolerance, ability to colonize and survive in the intestine, production of antibacterial substances, and immunomodulatory activity. Many literatures have reported and confirmed that probiotics have physiological functions such as anti-tumor, anti-cancer and anti-mutation, lowering blood pressure, and maintaining intestinal integrity. In addition, probiotics also have a lipid-lowering effect, a function that has attracted great attention from relevant researchers at home and abroad. Summary of the invention

[0004] Therefore, the technical problem to be solved by the present invention is to provide a use of a composite probiotic composition in the preparation of a drug for preventing, alleviating, assisting in the treatment or treating hyperlipidemia.

[0005] To this end, the present invention provides the following technical solutions:

[0006] A use of a composite probiotic composition in preparing a drug for preventing, alleviating, assisting in the treatment or treating hyperlipidemia, the composite probiotic composition comprising:

[0007] Lactobacillus casei Zhang, with a deposit number of CGMCC No. 5469;

[0008] Bifidobacterium animalis subsp. lactis V9, with the deposit number of CGMCC No.5470;

[0009] Lactobacillus plantarum P-8, deposit number is CGMCC No.6312;

[0010] Lactobacillus rhamnosus Probio-M9, deposited under CGMCC No. 18639; and

[0011] Bifidobacterium lactis Probio-M8 (Bifidobacterium lactis Probio-M8), the deposit number is CGMCC No.18610.

[0012] Optionally, the total viable count of the composite probiotic composition is not less than 3.0×10 10 cfu / g, the number of viable bacteria per strain is not less than 6.0×10 9 cfu / g.

[0013] Optionally, the raw material of each bacterial strain includes any one of the culture, fermentation product or lyophilized powder of the bacterial strain;

[0014] Optionally, the raw material of each bacterial strain is freeze-dried powder of the bacterial strain.

[0015] Optionally, auxiliary materials may also be included;

[0016] Optionally, the auxiliary material is prebiotics or dietary fiber;

[0017] Optionally, the auxiliary material includes at least one of galacto-oligosaccharide, fructo-oligosaccharide, inulin and polydextrose;

[0018] Optionally, the amount of the auxiliary material added is 1.0%-50.0wt% of the total mass of the composite probiotic composition.

[0019] Optionally, a method for preparing the composite probiotic composition is also included, comprising the step of mixing raw materials containing various strains of bacteria;

[0020] Optionally, the method further includes the step of mixing the raw materials containing the various strains of bacteria and then adding auxiliary materials.

[0021] Optionally, the composite probiotic composition also has the use of any one of the following (a)-(f):

[0022] (a) Use in the preparation of a drug for reducing visceral fat

[0023] (b) Use in the preparation of a medicament for lowering blood cholesterol content;

[0024] (c) Use in the preparation of a medicament for reducing the level of low-density lipoprotein in blood;

[0025] (d) Use in the preparation of a drug for increasing the level of high-density lipoprotein in blood;

[0026] (e) Use in the preparation of a medicament for inhibiting an increase in the D-lactic acid content in the blood or reducing the D-lactic acid content in the blood;

[0027] (f) Use in the preparation of a medicament for reducing the diamine oxidase content in blood;

[0028] (g) Use in the preparation of direct-injection starter cultures.

[0029] A use of a composite probiotic composition in preparing food, wherein the composite probiotic composition is composed of the following probiotics:

[0030] Lactobacillus casei Zhang, with a deposit number of CGMCC No. 5469;

[0031] Bifidobacterium animalis subsp. lactis V9, with the deposit number of CGMCC No.5470;

[0032] Lactobacillus plantarum P-8, deposit number is CGMCC No.6312;

[0033] Lactobacillus rhamnosus Probio-M9, deposited under CGMCC No. 18639; and

[0034] Bifidobacterium lactis Probio-M8 (Bifidobacterium lactis Probio-M8), the deposit number is CGMCC No.18610.

[0035] Optionally, the food includes ordinary food, health food and auxiliary therapeutic food.

[0036] Optionally, the food includes food prepared by fermenting the composite probiotic composition as a starter.

[0037] Optionally, the food includes soy products, dairy products or fruit and vegetable products.

[0038] The technical solution of the present invention has the following advantages:

[0039] 1. The present invention provides a composite probiotic composition for use in preparing a drug for preventing, alleviating, assisting in the treatment or treating hyperlipidemia, wherein the composite probiotic composition comprises: Lactobacillus caseiZhang, with a preservation number of CGMCC No.5469; Bifidobacterium animalissubsp.lactis V9, with a preservation number of CGMCC No.5470; Lactobacillus plantarum P-8, with a preservation number of CGMCC No.6312; Lactobacillus rhamnosus Probio-M9, with a preservation number of CGMCC No.18639; and Bifidobacterium lactis Probio-M8, with a preservation number of CGMCC No. No.18610; The above-mentioned composite probiotic composition has the function of preventing, alleviating, assisting in the treatment or treating hyperlipidemia, and has great application prospects in the preparation of drugs for alleviating and treating hyperlipidemia and other such diseases.

[0040] 2. Use of a composite probiotic composition provided by the present invention in the preparation of a drug for preventing, alleviating, assisting in the treatment or treating hyperlipidemia, wherein the total viable count of the probiotic composition is not less than 3.0×10 10 cfu / g, the number of viable bacteria per strain is not less than 6.0×10 9 cfu / g; the above-mentioned composite probiotic composition can significantly improve the related symptoms of hyperlipidemia by regulating the intestinal flora of the human body. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0042] Figure 1 The changes in LDL-C levels in the subjects of the probiotic group and the placebo group before and after the intervention in the experimental example of the present invention; the values ​​in brackets on the abscissa are the values ​​corresponding to the ordinate.

[0043] Figure 2 The TC content changes in the subjects of the probiotic group and the placebo group before and after the intervention in the experimental example of the present invention; the values ​​in the brackets on the abscissa are the values ​​corresponding to the ordinate.

[0044] Figure 3 The changes in HDL-C levels in the subjects of the probiotic group and the placebo group before and after the intervention in the experimental example of the present invention; the values ​​in brackets on the abscissa are the values ​​corresponding to the ordinate.

[0045] Figure 4 The figure shows the changes in D-lactic acid content in the subjects of the probiotic group and the placebo group before and after the intervention in the experimental example of the present invention; the values ​​in brackets on the abscissa are the values ​​corresponding to the ordinate.

[0046] Figure 5 The figure shows the changes in diamine oxidase content in the subjects of the probiotic group and the placebo group before and after the intervention in the experimental example of the present invention; the values ​​in brackets on the abscissa are the values ​​corresponding to the ordinate.

[0047] Figure 6 The figure shows the changes in visceral fat content in the subjects of the probiotic group and the placebo group before and after the intervention in the experimental example of the present invention; the values ​​in brackets on the abscissa are the values ​​corresponding to the ordinate. DETAILED DESCRIPTION

[0048] The following examples are provided for a better understanding of the present invention, but are not intended to limit the best mode of implementation, nor to limit the content and protection scope of the present invention. Any product identical or similar to the present invention obtained by anyone under the inspiration of the present invention or by combining the features of the present invention with other prior arts shall fall within the protection scope of the present invention.

[0049] If no specific experimental steps or conditions are specified in the examples, the conventional experimental steps or conditions described in the literature in the field can be used. If no manufacturer is specified for the reagents or instruments used, they are all conventional reagent products that can be obtained commercially.

[0050] Lactobacillus casei Zhang is a probiotic with multiple beneficial functions isolated from naturally fermented sour mare's milk in the Inner Mongolia prairie in 2002. It is the first probiotic in my country to complete whole genome sequencing. It was deposited in the General Microbiology Center of the China Microbiological Culture Collection Committee on November 18, 2011. The deposit address is No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing, and the deposit number is: CGMCC No. 5469. Experimental studies have found that L. casei Zhang intervention can accelerate fatty acid oxidation and thus play a role in lowering blood lipids.

[0051] Bifidobacterium animalis subsp. lactis V9 was deposited at the General Microbiological Center of China Microbiological Culture Collection Administration on November 18, 2011, with the deposit address of No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is: CGMCC No. 5470. Genomic studies have found that the strain has a very low probability of recombination and mutation and is genetically stable.

[0052] Lactobacillus plantarum P-8 is a strain of Lactobacillus plantarum with excellent probiotic properties, which was isolated from a naturally fermented yogurt sample from a herdsman's family on the grassland of Urad Middle Banner, Bayannaoer City, Inner Mongolia in 2005. It was deposited in the General Microbiology Center of China Microbiological Culture Collection Committee on June 28, 2012, with the deposit address of No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing, and the deposit number is: CGMCC No. 6312.

[0053] Lactobacillus rhamnosus Probio-M9 was isolated from breast milk of healthy women in 2017. The deposit number is: CGMCC No.18639.

[0054] Bifidobacterium lactis Probio-M8 was isolated from breast milk of healthy women in 2017. On October 8, 2019, it was deposited in the General Microbiology Center of China Microbiological Culture Collection Administration, with the deposit address at No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is: CGMCC No.18610.

[0055] The total number of viable bacteria of Lactobacillus casei Zhang, Bifidobacterium animalis subspecies lactis V9, Lactobacillus plantarum P-8, Lactobacillus rhamnosus Probio-M9 and Bifidobacterium lactis Probio-M8 in the composite probiotic powder is greater than or equal to 3.0×10 10 cfu / g.

[0056] The preparation method of probiotic powder comprises the following steps:

[0057] 1) Activation of strains: The strains (Lactobacillus casei Zhang, Bifidobacterium animalis lactis subsp. V9, Lactobacillus plantarum P-8, Lactobacillus rhamnosus Probio-M9 and Bifidobacterium lactis Probio-M8) stored at -40°C were inoculated into the corresponding liquid culture medium after sterilization at 121°C for 15 min, cultured anaerobically at 37°C for 18-24 h, and subcultured 1-2 times to obtain activated strains; the liquid culture medium corresponding to lactic acid bacteria (Lactobacillus casei Zhang, Lactobacillus plantarum P-8, Lactobacillus rhamnosus Probio-M9) was MRS liquid culture medium, and the liquid culture medium corresponding to bifidobacteria (Bifidobacterium animalis lactis subsp. V9 and Bifidobacterium lactis Probio-M8) was TPY liquid culture medium.

[0058] 2) Optimize the preparation of culture medium:

[0059] The components of the optimized culture medium were prepared in proportion, mixed evenly, adjusted to pH 6.5, and sterilized at 121°C for 15 min;

[0060] The composition of the optimized culture medium for Bifidobacterium is as follows: 12.0Kg of lactose, 7.0Kg of beef extract, 7.0Kg of yeast powder, 12.0Kg of casein peptone, 7.0Kg of soy peptone, 4.0Kg of KH2PO4, 1.0Kg of K2HPO4, 0.05Kg of MgSO4, 0.15Kg of Tween-80, 0.7Kg of L-cysteine ​​hydrochloride, 1.2Kg of calcium carbonate, and 1000L of distilled water.

[0061] The composition of the optimized culture medium for lactic acid bacteria is as follows: sucrose 23.5Kg, lactose 12.0Kg, soy peptone 15.0Kg, yeast powder 5.0Kg, yeast peptone 12Kg, Na2HPO3 21.0Kg, citric acid 2.0Kg, MgSO4·7H2O 0.6Kg, MnSO4 5H2O0.3Kg, Tween-80 1.0Kg, L-cysteine ​​hydrochloride 0.3Kg, and distilled water 1000L.

[0062] 3) Preparation of seed solution:

[0063] Take each activated bacterial strain in step 1) and inoculate it into the optimized culture medium prepared in step 2), and culture it anaerobically at 37° C. until the pH value is 4.5-4.8;

[0064] 4) Inoculation and fermentation:

[0065] The seed solution of step 3) was inoculated into the optimized medium prepared in step 2) at 1‰, and fermented for 18 hours under controlled fermentation conditions;

[0066] The fermentation conditions were controlled as follows: constant temperature culture at 30°C in the early stage of fermentation, and natural fermentation until the pH reached 5.0; then the fermentation temperature was adjusted to constant temperature culture at 37°C, and the pH was controlled to remain at 6.0, and anaerobic fermentation was maintained until the total fermentation time was 18 hours.

[0067] In the above process, pH is controlled by adding a neutralizing agent, wherein the neutralizing agent is NaOH.

[0068] The anaerobic condition was achieved by aerating nitrogen every two hours.

[0069] 5) Stop fermentation

[0070] When the bacteria stopped producing acid, the fermentation was terminated and the high-density fermentation liquid of each strain was obtained. The number of live bacteria in the fermentation liquid reached 2×10 10 cfu / ml and above.

[0071] Whether the acid production has stopped can be determined by the fact that the pH no longer decreases and the addition of the neutralizer stops.

[0072] 6) Freeze drying

[0073] a. Bacteria concentration: The high-density fermentation broth is centrifuged at 12000g to concentrate the bacteria;

[0074] b. Add protective agent: Add 3-8 times the volume of protective agent solution to the bacterial concentrate; the protective agent solution is composed of: skim milk 10-15Kg, lactose 8-12Kg, vitamin C 1-2Kg, sodium glutamate 1-2Kg, distilled water 1000L.

[0075] c. Drying: The bacterial suspension after adding the protective agent was freeze-dried to obtain freeze-dried bacterial powder of each strain of bacteria, and the total number of viable bacteria in each bacterial powder reached 6.0×10 11 cfu / g or above.

[0076] Example 1

[0077] A composite probiotic composition, comprising: 0.01 g of Lactobacillus casei Zhang powder, 0.01 g of Bifidobacterium animalis subspecies lactis V9 powder, 0.01 g of Lactobacillus plantarum P-8 powder, 0.01 g of Lactobacillus rhamnosus Probio-M9 powder, 0.01 g of Bifidobacterium lactis Probio-M8 powder, and 0.6 mg of maltodextrin as an auxiliary material.

[0078] The preparation method of the composite probiotic composition comprises weighing the freeze-dried powder of each strain of bacteria according to the formula, mixing them evenly, and then adding auxiliary materials and mixing them evenly.

[0079] Example 2

[0080] A composite probiotic composition, comprising: 0.01 g of Lactobacillus casei Zhang powder, 0.01 g of Bifidobacterium animalis subspecies V9 powder, 0.01 g of Lactobacillus plantarum P-8 powder, 0.01 g of Lactobacillus rhamnosus Probio-M9 powder, 0.01 g of Bifidobacterium lactis Probio-M8 powder, and 50 mg of inulin as an auxiliary material.

[0081] The preparation method of the composite probiotic composition comprises weighing the freeze-dried powder of each strain of bacteria according to the formula, mixing them evenly, and then adding auxiliary materials and mixing them evenly.

[0082] Example 3

[0083] A composite probiotic composition, comprising: 1 g of Lactobacillus casei Zhang powder, 1 g of Bifidobacterium animalis subspecies V9 powder, 1 g of Lactobacillus plantarum P-8 powder, 1 g of Lactobacillus rhamnosus Probio-M9 powder, 1 g of Bifidobacterium lactis Probio-M8 powder, and 1.5 g of polydextrose as an auxiliary material.

[0084] The preparation method of the composite probiotic composition comprises weighing the freeze-dried powder of each strain of bacteria according to the formula, mixing them evenly, and then adding auxiliary materials and mixing them evenly.

[0085] Experimental Example (I) Experimental Design:

[0086] Subjects: Subjects should be aged 18-70 years, regardless of gender, and meet any one or two of the following: triglycerides ≥ 1.8mmol / L, total cholesterol ≥ 5.7mmol / L. They have not used lipid-lowering drugs and do not plan to use them in the short term.

[0087] Inclusion criteria: Subjects are eligible for inclusion in this study only if they meet all of the following criteria.

[0088] 1. Both male and female, aged between 18 and 70 years old;

[0089] 2.BMI (Body Mass Index) is 24kg / m 2 -30kg / m 2 between;

[0090] 3. Male waist circumference ≥ 90cm, female waist circumference ≥ 85cm;

[0091] 4. No antibiotics were used in the month before enrollment;

[0092] 5. No history of chronic gastrointestinal disease;

[0093] 6. Agree to participate in this study and sign a written informed consent form;

[0094] 7. Patients with newly discovered or previous hyperlipidemia, without other complications, and without previous lipid-lowering drug treatment;

[0095] Exclusion criteria: Subjects who meet any of the following criteria will not be included:

[0096] 1. Women who are pregnant, breastfeeding or planning to become pregnant within 6 months;

[0097] 2. Patients with liver dysfunction: ALT and AST ≥ 2 times the upper limit of normal value or more; 3. Patients with renal dysfunction: glomerular filtration rate ≤ 90 ml / min / 1.72 m 2 ;

[0098] 4. Patients with hypertension whose blood pressure is still higher than 160 / 100 mmHg after treatment with more than 2 antihypertensive drugs; 5. Patients with heart failure;

[0099] 6. Those suffering from anemia or other blood diseases;

[0100] 7. Diabetic patients;

[0101] 8. Those with a history of allergy or hypersensitivity to lactic acid bacteria and their products;

[0102] 9. Those who have received other drug research within 3 months before screening;

[0103] Sample size: 200 cases in total. 100 cases in the simple high triglyceride group and 100 cases in the simple high total cholesterol group.

[0104] Main efficacy indicators: At the end of three months of treatment, blood triglyceride and total cholesterol levels reached the target (triglyceride <1.8mmol / L, total cholesterol <5.7mmol / L);

[0105] 2. Research Methods

[0106] 1. Description of intestinal probiotic preparations and placebo

[0107] This study adopted a double-blind method. The probiotic group and the placebo group were given the same diet and exercise guidance. The probiotic group took 2g of the composite probiotic composition of Example 1 (total viable bacteria count was not less than 30 billion cfu / d) daily, and the placebo group was given 2g / day of a placebo (maltodextrin) with the same packaging, color, and smell as the probiotics. A three-month follow-up observation was conducted and blood and fecal samples were collected at the beginning (0d) and end (90d) of the trial. (A randomized double-blind, non-interventional, parallel controlled clinical study, patients were randomly assigned to the placebo group and the probiotic group at a ratio of 1:1.)

[0108] 2. How to use intestinal probiotic preparations

[0109] Take directly orally, or with warm water (below 40°C), once a day, 1 packet each time.

[0110] 3. Treatment

[0111] The total course of treatment is 3 months, and the follow-up observation period is 3 months.

[0112] 4. Combined medication

[0113] During the treatment, other combined drugs may be used under the guidance of the investigator if they are necessary for the safety and health of the subjects, as long as the use of the drug has no effect on the efficacy evaluation of the study drug. All combined drugs and their doses, dose adjustments, and start and end times are recorded on the CRF.

[0114] 5. Prohibited drugs

[0115] The following drugs should not be used during the treatment study: antibiotics, other intestinal flora preparations, or drugs that may interfere with intestinal flora

[0116] 6. Standard treatment for drug withdrawal

[0117] (1) ALT or AST is greater than 2 times the upper limit of normal:

[0118] (2) SCr is greater than the upper limit of normal value;

[0119] (3) White blood cell count <3.0 × 10 9 / L;

[0120] (4) Platelet count <80×10 9 / L;

[0121] (5) Absolute neutrophil count <1.5×10 9 / L.

[0122] If any of the above situations occur, the drug should be discontinued for 7 days and the indicators should be rechecked. If the drug use standard is not met, the study will be terminated; if it returns to normal, the drug will continue to be used. If the situation that meets the "drug discontinuation standard" occurs twice during the study, the study will be terminated.

[0123] (III) Test methods and results

[0124] 1. This study adopted a double-blind method, and the 70 subjects finally included were randomly assigned to a placebo group (35 people) and a probiotic group (35 people) at a ratio of 1:1. Both groups were given the same diet and exercise guidance. The probiotic group took 2g of the composite probiotic composition (30 billion cfu / d) daily, and the placebo group was given a placebo (maltodextrin) 2g / day with the same packaging, color, smell and probiotics. A three-month follow-up observation was conducted and blood and fecal samples were collected at the beginning (0d) and end (90d) of the trial to comprehensively observe the clinical effects on patients with hyperlipidemia and the changes in adipose factors in the process of glucose and lipid metabolism.

[0125] 2. Index test

[0126] The LDL-C level, TC level in the blood, HDL-C level, D-lactic acid level, diamine oxidase level and visceral fat level in the subjects of the probiotic group and the placebo group were detected at the beginning (0d) and at the end of three months (90d). LDL-C (normal value <3.37mmol / L), TC (normal value <5.18mmol / L), HDL-C (normal value>1.04mmol / L), D-lactic acid (normal value <15mmol / L), diamine oxidase (normal value <10mmol / L), visceral fat (normal value <100cm 2 ).

[0127] Blood samples were collected from each group of subjects at month 0 (no medication on day 0) and after 3 months of treatment (day 90) to measure the following indicators:

[0128] LDL-C content: This test kit is composed of Provided, model E-BC-K221-M. A detection method for quantitatively determining LDL-C by a combined shielding method. This method uses a liquid double reagent, which is composed of reagent 1 and reagent 2 placed separately, wherein the reagent 1 contains divalent metal chloride calcium chloride, whose concentration range is 0.4g / L-0.5g / L, the LDL-C monoclonal antibody is an apolipoprotein B monoclonal antibody, whose concentration range is 50ml / L-150ml / L, and a quantitative enzyme reagent; the reagent 2 contains a surfactant, a color developer, a preservative, an anti-interference substance and a reaction accelerator. The method has good color development characteristics, high accuracy, and stable reagent components.

[0129] TC content in blood: using a kit detection method, provided by Beijing Regen Biotechnology Co., Ltd., named Total Cholesterol (TC) Detection Kit (COD-PAP Single Reagent Microplate Method);

[0130] HDL-C content: using the kit detection method, provided by Ilicon, named High-density lipoprotein cholesterol (HDL-C) detection kit (direct method), catalog number L7003;

[0131] D-lactic acid content: using a kit detection method, provided by Beijing Regen Biotechnology Co., Ltd., named D-lactic acid detection kit (lactate dehydrogenase colorimetric method);

[0132] Diamine oxidase content: using the kit detection method, provided by Beijing Solebow Technology Co., Ltd., the name is diamine oxidase activity detection kit, catalog number BC1285;

[0133] Visceral fat mass: measured using dual-energy X-ray absorptiometry.

[0134] 3. Test results

[0135] (1) By Figure 1 It was found that compared with the placebo group, the probiotic group could significantly reduce the LDL-C content in the blood of patients with hyperlipidemia (23 / 35 people were reduced, P=0.0086).

[0136] (2) By Figure 2 It was found that probiotics could also significantly reduce the TC content in the blood (24 / 35 subjects were reduced, P=0.0017), while placebo intervention had no significant change (P=0.10).

[0137] (3) By Figure 3 It was found that probiotic intervention could significantly increase the HDL-C content in the subjects (15 / 35 people increased, P=0.023), while the HDL-C content in the volunteers significantly decreased after placebo intervention (26 / 35 people decreased, P=0.0016).

[0138] (4) By Figure 4 It was found that compared with the placebo, probiotics could significantly inhibit the increase of D-lactic acid content in the blood of subjects, and also caused a very significant decrease in D-lactic acid in the blood of some subjects (P<0.0001), and the higher the initial content, the greater the decrease (r=0.93, P<0.0001).

[0139] (5) By Figure 5 It was found that although the diamine oxidase in the blood of the vast majority of subjects (67 / 70 people) was within the normal range, the diamine oxidase in the blood of the volunteers in the placebo group increased significantly (P=0.0014), while probiotics could significantly reduce the diamine oxidase in the volunteers (P=0.0023).

[0140] (6) By Figure 6 It was found that the visceral fat in both the probiotic group and the placebo group decreased significantly (P<0.05), but the decrease in the probiotic group was greater than that in the placebo group. This indicates that the probiotic group can significantly improve the symptoms related to hyperlipidemia.

[0141] In summary, taking the composite probiotic composition of the present invention is safe and can be effectively used to treat patients with hyperlipidemia, which further illustrates that the composite probiotic composition has a certain effect of improving the symptoms of patients with hyperlipidemia.

[0142] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.

Claims

1. Use of a composite probiotic composition in the preparation of a drug for preventing, alleviating, assisting in the treatment or treating hyperlipidemia, characterized in that: The composite probiotic composition is composed of the following probiotics: Lactobacillus casei Zhang Lactobacillus casei Zhang), the deposit number is CGMCC No.5469; Bifidobacterium animalis subsp. lactis V9), the deposit number is CGMCC No.5470; Lactobacillus plantarum P-8 ( Lactobacillus plantarum P-8), the deposit number is CGMCC No.6312; Lactobacillus rhamnosus Probio-M9 ( Lactobacillus rhamnosus Probio-M9), deposited under the number CGMCC No.18639; and Bifidobacterium lactis Probio-M8 ( Bifidobacterium lactis Probio-M8), the deposit number is CGMCC No.18610; The prevention, relief, auxiliary treatment or treatment of hyperlipidemia is to reduce visceral fat, reduce blood cholesterol content, reduce blood low-density lipoprotein content, increase blood high-density lipoprotein content, inhibit the increase of blood D-lactic acid content, reduce blood D-lactic acid content and reduce blood diamine oxidase content.

2. The use according to claim 1, characterized in that The total viable bacteria count of the composite probiotic composition is not less than 3.0×10 10 cfu / g, the number of viable bacteria per strain is not less than 6.0×10 9 cfu / g.

3. The use according to claim 2, characterized in that: The raw material of each bacterial strain includes any one of the culture, fermentation product or freeze-dried powder of the bacterial strain.

4. The use according to claim 3, characterized in that The raw material of each bacterial strain is the freeze-dried powder of the bacterial strain.

5. The use according to any one of claims 1 to 4, characterized in that: Also includes auxiliary materials.

6. The use according to claim 5, characterized in that The auxiliary material is prebiotics or dietary fiber.

7. The use according to claim 6, characterized in that The auxiliary material comprises at least one of galacto-oligosaccharide, fructo-oligosaccharide, inulin and polydextrose.

8. The use according to claim 7, characterized in that The amount of the auxiliary material added is 1.0%-50.0wt% of the total weight of the composite probiotic composition.

9. The use according to any one of claims 1 to 4, characterized in that The invention also comprises a method for preparing the composite probiotic composition, which comprises the step of mixing raw materials containing various strains of bacteria.

10. The use according to claim 9, characterized in that The method also includes the step of mixing the raw materials containing the various strains of bacteria and then adding auxiliary materials.

11. Use of a composite probiotic composition in preparing food, characterized in that: The composite probiotic composition is composed of the following probiotics: Lactobacillus casei Zhang Lactobacillus casei Zhang), the deposit number is CGMCC No.5469; Bifidobacterium animalis subsp. lactis V9), the deposit number is CGMCC No.5470; Lactobacillus plantarum P-8 ( Lactobacillus plantarum P-8), the deposit number is CGMCC No.6312; Lactobacillus rhamnosus Probio-M9 ( Lactobacillus rhamnosus Probio-M9), deposited under the number CGMCC No.18639; and Bifidobacterium lactis Probio-M8 ( Bifidobacterium lactis Probio-M8), the deposit number is CGMCC No.18610.

12. The use according to claim 11, characterized in that The food includes ordinary food or health food.

13. The use according to claim 11 or 12, characterized in that The food includes food prepared by fermenting the composite probiotic composition as a starter.

14. The use according to claim 11 or 12, characterized in that The food includes soy products, dairy products or fruit and vegetable products.